您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Bradykinin(1-7)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Bradykinin(1-7)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Bradykinin(1-7)图片
CAS NO:23815-87-4
包装与价格:
包装价格(元)
5mg电议
10mg电议
50mg电议
100mg电议

产品名称
Bradykinin Fragment 1-7
产品介绍
Bradykinin (1-7) 是一种氨基截短的激肽肽。Bradykinin (1-7) 是由内肽酶切割形成的一种 Bradykinin 代谢物。
生物活性

Bradykinin (1-7) is an amino-truncated Bradykinin peptide. Bradykinin (1-7) is a metabolite of Bradykinin, cleaved by endopeptidase.

体外研究
(In Vitro)

The Bradykinin peptide system is a tissue-based system with potent cardiovascular and renal effects. To investigate the regulation of this system, a highly sensitive amino terminal-directed radioimmunoassay that, with high performance liquid chromatography, enables the measurement of Bradykinin-(1-7), Bradykinin-(1-8), and Bradykinin-(1-9), is developed. Together with a carboxy terminal-directed radioimmunoassay, Bradykinin peptides in rat kidney and blood are characterized. The predominant Bradykinin peptides in kidney are Bradykinin-(1-9) (~100 fmol/g wet weight of tissue) and Bradykinin-(1-7) (~70 fmol/g), with low levels of Bradykinin-(1-8) (~8 fmol/g) and Bradykinin-(4-9) (~12 fmol/g) detectable; Bradykinin-(2-9) and Bradykinin-(3-9) are below the limits of detection. In blood, the levels of Bradykinin-(1-9) are very low (~2 fmol/ml), and other Bradykinin peptides are below the limits ofdetection. Administration of the angiotensin converting enzyme (ACE) inhibitor Perindopril is associated with an approximate twofold increase in renal levels of Bradykinin-(1-8) and Bradykinin-(1-9) and a decrease in the Bradykinin-(1-7)/Bradykinin-(1-9) ratio. The amino terminal-directed radioimmunoassay is also applied to heart, aorta, brown adipose tissue, adrenal, lung, and brain. For these tissues, Bradykinin-(1-7) and Bradykinin-(1-9) are of similar abundance (16-340 fmol/g), with lower levels of Bradykinin-(1-8)[1].

分子量

756.85

性状

Solid

Formula

C35H52N10O9

CAS 号

23815-87-4

Sequence

Arg-Pro-Pro-Gly-Phe-Ser-Pro

Sequence Shortening

RPPGFSP

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture

Powder-80°C2 years
-20°C1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶解性数据
In Vitro: 

H2O : 100 mg/mL(132.13 mM;Need ultrasonic)

配制储备液
浓度溶剂体积质量1 mg5 mg10 mg
1 mM1.3213 mL6.6063 mL13.2127 mL
5 mM0.2643 mL1.3213 mL2.6425 mL
10 mM0.1321 mL0.6606 mL1.3213 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: PBS

    Solubility: 100 mg/mL (132.13 mM); Clear solution; Need ultrasonic

*以上所有助溶剂都可在本网站选购。